All In Biotech

Drug Trial Radar · NCT04752215

A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface

A First-in-human Phase I, Non-randomized, Open-label, Multi-center Dose-escalation Trial of BI 765049 and BI 765049 + Ezabenlimab Administered by Parenteral Administration(s) in Patients With Malignant Solid Tumors Expressing B7-H6.

Last checked: Nov 19, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

67

Actual

Start

May 18, 2021

Primary completion

Nov 19, 2024

Study completion Dec 17, 2024

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Feb 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with advanced solid tumors whose previous cancer treatment was not successful. People can participate if their tumor has the B7-H6 marker or if they have colorectal cancer. The study tests 2 medicines called BI 765049 and ezabenlimab (BI 754091). Both medicines may help the immune system fight cancer. The purpose of this study is to find out the highest dose of BI 765049 alone and in combination with ezabenlimab the participants can tolerate. In this study, BI 765049 is given to people for the first time. Participants can stay in the study for up to 3 years, if they benefit from treatment and can tolerate it. During this time, they get BI 765049 alone or in combination with ezabenlimab as infusion into a vein every 3 weeks. The doctors check the health of the participants and note any health problems that could have been caused by BI 765049 or ezabenlimab. The doctors also regularly monitor the size of the tumor.

Conditions

  • Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms

Interventions

  • BI 765049Drug

    BI 765049

  • ezabenlimabDrug

    ezabenlimab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) in any studied regimenTime frame: Up to 3 weeks
  2. Number of patients with dose limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation periodTime frame: Up to 3 weeks

Locations

14 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Valkyrie Clinical Trials

    Los Angeles, California

  • University of California Irvine

    Orange, California

  • HealthONE

    Denver, Colorado

  • MD Anderson Cancer Center Orlando

    Orlando, Florida

  • Florida Cancer Specialists-Sarasota-61670

    Sarasota, Florida

  • Northwestern University

    Chicago, Illinois

  • Norton Healthcare - Norton Cancer Institute - Louisville

    Louisville, Kentucky

  • New York University Langone Medical Center

    New York, New York

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Tennessee Oncology, PLLC-Nashville-52568

    Nashville, Tennessee

  • Mary Crowley Cancer Research Center

    Dallas, Texas

  • Baylor University Medical Center

    Dallas, Texas

  • Princess Margaret Cancer Centre

    Toronto, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.